Drug Search Results
More Filters [+]


Alternative Names: BAY-3375968, BAY 3375968, BAY3375968
Latest Update: 2023-09-28
Latest Update Note: Clinical Trial Update

Product Description

BAY3375968 is an antibody that binds to a protein called CCR8 which is located on the surface of regulatory T cells. This leads to a reduction in regulatory T cells and further inhibits their immune suppressive activity, so that the immune response against cancer can be strengthened as observed in animal models. Animal studies also showed that BAY3375968 may add more anti-cancer effect to immunotherapy with PD-1/PD-L1 inhibitors when used in combination. All of these previous observations need to be confirmed in humans. (Sourced from: https://clinicaltrials.bayer.com/study/21820/)

Mechanisms of Action: CCR8 Inhibitor

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BAY-3375968

Countries in Clinic: Canada, Singapore, United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Head and Neck Cancer|Heart Block|Heart Cancer|Melanoma|Non-Small-Cell Lung Cancer|Squamous Cell Carcinoma|Triple Negative Breast Cancer



Trial Status


Primary Completion Date

Probability of Success




Head and Neck Cancer|Heart Cancer|Non-Small-Cell Lung Cancer|Squamous Cell Carcinoma|Triple Negative Breast Cancer|Melanoma|Heart Block


Recent News Events